Compare Mesoblast Limited (MESO) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Ralph Lauren Corp — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Ralph Lauren Corp trades at $383.95 (market cap $22.41B). The key difference: Ralph Lauren Corp is far larger — about 10.3× Mesoblast Limited's market cap, and Ralph Lauren Corp pays a 0.99% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | RL | |
|---|---|---|
Market Cap | $2.17B | $22.41B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $414.25 |
52-Week Low | $12.88 | $283.34 |
Enterprise Value | $2.17B | $23.35B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Ralph Lauren (RL) trades at $376.55, down 1.03% on the day, with a neutral technical signal and key support at $370. The company demonstrates strong fundamentals, with revenue growing to $7.08B in 2025 and net income of $742.9M, supported by a 69.87% gross margin and consistent earnings beats. Analyst consensus is bullish with a $445.71 price target, and recent news highlights brand strength and digital expansion.
The outlook for RL is positive, driven by earnings momentum and strategic initiatives, though premium valuation and market volatility present risks. Upside potential exists if the company maintains its growth trajectory and meets Q2 2026 EPS expectations of $4.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
